• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Increased SARS-CoV-2-related hospitalization and mortality in rheumatoid arthritis patients receiving rituximab therapy-a monocentric retrospective study.

作者信息

Wang Chrong-Reen, Hsu Chih-Hui, Lin Wei-Chieh

机构信息

Division of Rheumatology and Immunology, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.

Biostatistics Consulting Center, Clinical Medicine Research Center, National Cheng Kung University Hospital, Tainan, Taiwan.

出版信息

J Microbiol Immunol Infect. 2025 Apr;58(2):272-275. doi: 10.1016/j.jmii.2025.01.004. Epub 2025 Jan 28.

DOI:10.1016/j.jmii.2025.01.004
PMID:39904705
Abstract

From 2022 April to 2024 August, retrospective analyses by multivariable logistic regression were conducted in 341 rheumatoid arthritis patients receiving rituximab (RTX), tofacitinib (TOF) or disease-modifying-anti-rheumatic drug (DMARD) alone therapy. Compared to DMARD alone or TOF treatment, RTX therapy had increased adjusted odds ratios of SARS-CoV-2-related hospitalization, pneumonia and mortality.

摘要

相似文献

1
Increased SARS-CoV-2-related hospitalization and mortality in rheumatoid arthritis patients receiving rituximab therapy-a monocentric retrospective study.
J Microbiol Immunol Infect. 2025 Apr;58(2):272-275. doi: 10.1016/j.jmii.2025.01.004. Epub 2025 Jan 28.
2
Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis.生物制剂或托法替布用于对甲氨蝶呤或其他传统改善病情抗风湿药物反应不完全的类风湿关节炎患者：一项系统评价和网状Meta分析
Cochrane Database Syst Rev. 2016 May 13;2016(5):CD012183. doi: 10.1002/14651858.CD012183.
3
The T-cell response to SARS-CoV- 2 vaccination persists beyond six months in rheumatoid arthritis patients treated with rituximab.在用利妥昔单抗治疗的类风湿性关节炎患者中，T细胞对SARS-CoV-2疫苗接种的反应持续超过六个月。
Arthritis Res Ther. 2025 Apr 16;27(1):86. doi: 10.1186/s13075-025-03553-4.
4
Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study.类风湿关节炎患者接受利妥昔单抗治疗时HBsAg阴性/抗-HBc阳性携带者的乙肝病毒再激活风险低：一项意大利多中心回顾性研究
J Rheumatol. 2016 May;43(5):869-74. doi: 10.3899/jrheum.151105. Epub 2016 Feb 15.
5
Results of a 12-Week Open-Label, Non-Interventional Study of the Efficacy and Safety of Olokizumab Therapy in Patients with Rheumatoid Arthritis after Switching from Anti-B-Cell Therapy during the SARS-CoV-2 Pandemic.在严重急性呼吸综合征冠状病毒2（SARS-CoV-2）大流行期间，从抗B细胞疗法转换后，奥洛珠单抗治疗类风湿性关节炎患者的疗效和安全性的12周开放标签、非干预性研究结果。
Dokl Biochem Biophys. 2024 Oct;518(1):291-299. doi: 10.1134/S1607672924701060. Epub 2024 Jul 1.
6
Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials.托珠单抗、利妥昔单抗、阿巴西普和托法替布在对肿瘤坏死因子抑制剂反应不足的活动性类风湿关节炎患者中的疗效和安全性比较：一项随机对照试验的贝叶斯网络荟萃分析。
Int J Rheum Dis. 2016 Nov;19(11):1103-1111. doi: 10.1111/1756-185X.12822. Epub 2015 Dec 22.
7
Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).生物制剂或托法替布单药治疗传统抗风湿药物（DMARD）治疗失败的类风湿关节炎患者：一项Cochrane系统评价和网状Meta分析（NMA）
Cochrane Database Syst Rev. 2016 Nov 17;11(11):CD012437. doi: 10.1002/14651858.CD012437.
8
Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study.托法替布治疗类风湿关节炎的疗效和安全性：一项队列研究。
Arthritis Res Ther. 2018 Mar 23;20(1):60. doi: 10.1186/s13075-018-1539-6.
9
High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study.由于 SARS-CoV-2 感染，接受利妥昔单抗治疗的风湿性疾病患者出现严重疾病和死亡的比率较高：一项描述性研究。
Rheumatol Int. 2020 Dec;40(12):2015-2021. doi: 10.1007/s00296-020-04699-x. Epub 2020 Sep 18.
10
Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.托法替布治疗疾病修饰抗风湿药物治疗失败后的类风湿关节炎：NICE 单技术评估的循证评价组观点。
Pharmacoeconomics. 2018 Sep;36(9):1063-1072. doi: 10.1007/s40273-018-0639-0.